Impact of T h 1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques

Authors:

Abstract
The results of the RV144 trial demonstrated that vaccination could prevent HIV transmission in humans and that longevity of anti-Env antibodies may be key to this protection. Efforts to improve upon the prime-boost vaccine regimen used in RV144 have indicated that booster immunizations can increase serum anti-Env antibody titers but only transiently. Poor antibody durability hampers efforts to develop an effective HIV-1 vaccine. This study was designed to identify the specific elements involved in the immunological mechanism necessary to produce robust HIV-1-specific antibodies in rhesus macaques. By clearly defining immune-mediated pathways that improve the magnitude and functionality of the anti-HIV-1 antibody response, we will have the foundation necessary for the rational development of an HIV-1 vaccine.
Funding Information
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (R03AI138792)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (1R21AI34368)
  • HHS | NIH | NIH Office of the Director (K01 OD023034)

This publication has 74 references indexed in Scilit: